MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics, Inc. (IKT)

|||

Balance Sheets Overview

Current Ratio
1582.30%
Quick Ratio
1582.30%
Debt to Asset Ratio
6.27%
Unit: Dollar
Assets Breakdown
    • Cash and cash equivalents
    • Prepaid research and development
    • Prepaid research and development...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accounts payable
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
31,206,707
49,573,510
139,220,208
38,269,706
Marketable securities
127,812,140
120,795,235
39,543,820
39,052,511
Prepaid research and development
2,346,641
514,910
1,001,993
210,566
Prepaid expenses and other current assets
933,938
1,292,813
343,374
618,783
Deferred offering costs
44,489
-
-
385,062
Total current assets
162,343,915
172,176,468
180,109,395
78,536,628
Equipment and improvements, net
-
-
0
0
Right-of-use asset
-
-
0
0
Prepaid research and development, noncurrent
1,000,000
1,000,000
1,000,000
1,000,000
Other assets
244,697
155,759
95,121
57,913
Total assets
163,588,612
173,332,227
181,204,516
79,594,541
Accounts payable
991,720
1,587,305
1,158,054
620,528
Lease obligation, current
-
-
0
0
Accrued expenses and other current liabilities
9,268,306
4,124,654
4,081,282
3,656,383
Contingent consideration liability
0
0
3,061,501
2,419,332
Total current liabilities
10,260,026
5,711,959
8,300,837
6,696,243
Total liabilities
10,260,026
5,711,959
8,300,837
6,696,243
Common stock, 0.001 par value 500,000,000 shares authorized 132,032,636 and 131,691,237 shares issued and outstanding (including 0 and 4,149,252 contingently issuable shares - see note 10) at june 30, 2026 and december 31, 2025, respectively
132,032
132,032
131,691
74,808
Additional paid-in capital
331,921,179
326,575,169
315,429,986
202,772,828
Accumulated other comprehensive income (loss)
-72,754
-26,293
21,802
-4,189
Accumulated deficit
-178,651,871
-159,060,640
-142,679,800
-129,945,149
Total stockholders' equity
153,328,586
167,620,268
172,903,679
72,898,298
Total liabilities and stockholders' equity
163,588,612
173,332,227
181,204,516
79,594,541
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Marketable securities$127,812,140 (1188.03%↑ Y/Y)Cash and cashequivalents$31,206,707 (-59.86%↓ Y/Y)Prepaid research anddevelopment$2,346,641 (1589.99%↑ Y/Y)Prepaid expenses andother current assets$933,938 (36.82%↑ Y/Y)Deferred offering costs$44,489 (-85.53%↓ Y/Y)Total current assets$162,343,915 (82.83%↑ Y/Y)Prepaid research anddevelopment, noncurrent$1,000,000 Other assets$244,697 Total assets$163,588,612 (84.11%↑ Y/Y)Total liabilities andstockholders' equity$163,588,612 (84.11%↑ Y/Y)Total stockholders'equity$153,328,586 (91.53%↑ Y/Y)Total liabilities$10,260,026 (16.60%↑ Y/Y)Accumulated deficit-$178,651,871 (-51.38%↓ Y/Y)Accumulated othercomprehensive income (loss)-$72,754 (-2371.26%↓ Y/Y)Additional paid-in capital$331,921,179 (67.64%↑ Y/Y)Total currentliabilities$10,260,026 (16.60%↑ Y/Y)Common stock, 0.001 parvalue 500,000,000...$132,032 (77.19%↑ Y/Y)Accrued expenses andother current...$9,268,306 (194.62%↑ Y/Y)Accounts payable$991,720 (-63.32%↓ Y/Y)